Liu Y, Li Y, Liu Y, Zhang Z, Gao Y
Front Oncol. 2024; 14:1404799.
PMID: 39007100
PMC: 11239389.
DOI: 10.3389/fonc.2024.1404799.
Choi H, Ju S, Kang K, Seo M, Kim J, Miyoshi E
Front Oncol. 2023; 13:1183442.
PMID: 37168374
PMC: 10165115.
DOI: 10.3389/fonc.2023.1183442.
Roderburg C, Labuhn S, Bednarsch J, Lang S, Schneider A, Hammerich L
Mediators Inflamm. 2022; 2022:6195004.
PMID: 36505756
PMC: 9731746.
DOI: 10.1155/2022/6195004.
He S, Zeng F, Yin H, Wang P, Bai Y, Song Q
EClinicalMedicine. 2022; 55:101736.
PMID: 36425869
PMC: 9678809.
DOI: 10.1016/j.eclinm.2022.101736.
Gorji L, Beal E
Curr Oncol. 2022; 29(9):6674-6687.
PMID: 36135093
PMC: 9498206.
DOI: 10.3390/curroncol29090524.
Development and validation of a machine learning-based nomogram for prediction of intrahepatic cholangiocarcinoma in patients with intrahepatic lithiasis.
Shen X, Zhao H, Jin X, Chen J, Yu Z, Ramen K
Hepatobiliary Surg Nutr. 2022; 10(6):749-765.
PMID: 35004943
PMC: 8683924.
DOI: 10.21037/hbsn-20-332.
Surgical management of biliary malignancy.
Kingham T, Aveson V, Wei A, Castellanos J, Allen P, Nussbaum D
Curr Probl Surg. 2021; 58(2):100854.
PMID: 33531120
PMC: 8022290.
DOI: 10.1016/j.cpsurg.2020.100854.
Current management of intrahepatic cholangiocarcinoma: from resection to palliative treatments.
Bartolini I, Risaliti M, Fortuna L, Agostini C, Ringressi M, Taddei A
Radiol Oncol. 2020; 54(3):263-271.
PMID: 32726292
PMC: 7409608.
DOI: 10.2478/raon-2020-0045.
Circulating TGF-β1 as the potential epithelial mesenchymal transition-biomarker for diagnosis of cholangiocarcinoma.
Kimawaha P, Jusakul A, Junsawang P, Loilome W, Khuntikeo N, Techasen A
J Gastrointest Oncol. 2020; 11(2):304-318.
PMID: 32399272
PMC: 7212108.
DOI: 10.21037/jgo.2019.01.03.
Management Strategies for Patients with Hilar Cholangiocarcinomas: Challenges and Solutions.
Mehrotra S, Lalwani S, Nundy S
Hepat Med. 2020; 12:1-13.
PMID: 32158282
PMC: 6986165.
DOI: 10.2147/HMER.S223022.
Biomarkers in cholangiocarcinoma.
Marrero J
Clin Liver Dis (Hoboken). 2019; 3(5):101-103.
PMID: 30992898
PMC: 6448710.
DOI: 10.1002/cld.345.
Monitoring outcomes in intrahepatic cholangiocarcinoma patients following hepatic resection.
Rahnemai-Azar A, Pandey P, Kamel I, Pawlik T
Hepat Oncol. 2018; 3(4):223-239.
PMID: 30191045
PMC: 6095314.
DOI: 10.2217/hep-2016-0009.
Systematic literature review of IL-6 as a biomarker or treatment target in patients with gastric, bile duct, pancreatic and colorectal cancer.
Vainer N, Dehlendorff C, Johansen J
Oncotarget. 2018; 9(51):29820-29841.
PMID: 30038723
PMC: 6049875.
DOI: 10.18632/oncotarget.25661.
A novel nomogram for the prediction of intrahepatic cholangiocarcinoma in patients with intrahepatic lithiasis complicated by imagiologically diagnosed mass.
Chen G, Yu H, Wang Y, Li C, Zhou M, Yu Z
Cancer Manag Res. 2018; 10:847-856.
PMID: 29720881
PMC: 5918625.
DOI: 10.2147/CMAR.S157506.
Biomarkers for the Diagnosis of Cholangiocarcinoma: A Systematic Review.
Tshering G, Dorji P, Chaijaroenkul W, Na-Bangchang K
Am J Trop Med Hyg. 2018; 98(6):1788-1797.
PMID: 29637880
PMC: 6086160.
DOI: 10.4269/ajtmh.17-0879.
Opisthorchiasis and cholangiocarcinoma in Southeast Asia: an unresolved problem.
Hughes T, OConnor T, Techasen A, Namwat N, Loilome W, Andrews R
Int J Gen Med. 2017; 10:227-237.
PMID: 28848361
PMC: 5557399.
DOI: 10.2147/IJGM.S133292.
Cholangiocarcinoma: Biology, Clinical Management, and Pharmacological Perspectives.
Macias R
ISRN Hepatol. 2016; 2014:828074.
PMID: 27335842
PMC: 4890896.
DOI: 10.1155/2014/828074.
Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA).
Banales J, Cardinale V, Carpino G, Marzioni M, Andersen J, Invernizzi P
Nat Rev Gastroenterol Hepatol. 2016; 13(5):261-80.
PMID: 27095655
DOI: 10.1038/nrgastro.2016.51.
The Role of Biliary Carcinoembryonic Antigen-Related Cellular Adhesion Molecule 6 (CEACAM6) as a Biomarker in Cholangiocarcinoma.
Rose J, Correa-Gallego C, Li Y, Nelson J, Alseidi A, Helton W
PLoS One. 2016; 11(3):e0150195.
PMID: 26974538
PMC: 4790932.
DOI: 10.1371/journal.pone.0150195.
Serum microRNAs as novel biomarkers for primary sclerosing cholangitis and cholangiocarcinoma.
Bernuzzi F, Marabita F, Lleo A, Carbone M, Mirolo M, Marzioni M
Clin Exp Immunol. 2016; 185(1):61-71.
PMID: 26864161
PMC: 4908296.
DOI: 10.1111/cei.12776.